510(k) Report

510(k) · Cleared

Cleared

cNeuro cDAT

K233908510(k) TraditionalCleared Jul 1, 2024202-day reviewClass II21 CFR 892.2050

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Combinostics OY · LLZ System, Image Processing, Radiological

Cleared on Jul 1, 2024 as substantially equivalent to K201103 (GE Healthcare, 2020) after a 202-day review. Its family tree reaches back 11 generations to 2001.

Decided
Jul 1, 2024
Review
202 days
Class
Class II
Product code
LLZ
Recalls
None
Predicates
1

Its longest line of descent runs back 11 generations to K010641 (2001). 24 ancestors in all, the oldest K914350 (1991). No later device cites it as a predicate yet.

  1. Root · 11 generations backK010641 GE CT-Pet SystemGe Medical Systems, Inc. · 2001
  2. 7 generations between
  3. 3 generations backK130884 Xeleris 3.1 Processing and Review WorkstationGe Medical Systems F.I. Haifa · 2013
  4. 2 generations backK153355 Xeleris 4.0 Processing and Review WorkstationGE Healthcare · 2016
  5. 1 generation backK201103 Xeleris V Processing and Review SystemsGE Healthcare · 2020
  6. This deviceK233908 cNeuro cDATCombinostics OY · 2024
Show all 11 generations
  1. Root · 11 generations backK010641 GE CT-Pet SystemGe Medical Systems, Inc. · 2001
  2. 10 generations backK023988 GE Discovery LS SystemGE Medical Systems · 2003 · Recalled
  3. 9 generations backK040172 Modification to GE Discovery LS SystemGE Medical Systems · 2004 · Recalled
  4. 8 generations backK041543 GE Discovery STGE Healthcare · 2004 · Recalled
  5. 7 generations backK042863 SceniumSiemens Molecular Imaging, Ltd. · 2004
  6. 6 generations backK061545 Scenium 1.1Siemens Molecular Imaging, Ltd. · 2006
  7. 5 generations backK121074 Scenium 2.0Siemens Medical Solutions USA, Inc. · 2012
  8. 4 generations backK123528 SceniumSiemens Medical Solutions USA, Inc. · 2012
  9. 3 generations backK130884 Xeleris 3.1 Processing and Review WorkstationGe Medical Systems F.I. Haifa · 2013
  10. 2 generations backK153355 Xeleris 4.0 Processing and Review WorkstationGE Healthcare · 2016
  11. 1 generation backK201103 Xeleris V Processing and Review SystemsGE Healthcare · 2020
  12. This deviceK233908 cNeuro cDATCombinostics OY · 2024
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−11K010641GE CT-Pet SystemGe Medical Systems, Inc.2001—
−10K023988GE Discovery LS SystemGE Medical Systems20031
−9K040172Modification to GE Discovery LS SystemGE Medical Systems20045
−8K041543GE Discovery STGE Healthcare20041
−7K042863SceniumSiemens Molecular Imaging, Ltd.2004—
−6K061545Scenium 1.1Siemens Molecular Imaging, Ltd.2006—
−5K121074Scenium 2.0Siemens Medical Solutions USA, Inc.2012—
−4K123528SceniumSiemens Medical Solutions USA, Inc.2012—
−3K130884Xeleris 3.1 Processing and Review WorkstationGe Medical Systems F.I. Haifa2013—
−2K153355Xeleris 4.0 Processing and Review WorkstationGE Healthcare2016—
−1K201103Xeleris V Processing and Review SystemsGE Healthcare2020—
0 (this device)K233908cNeuro cDATCombinostics OY2024—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199120
199710
200020
200110
200220
200310
200410
200520
201010
FIG. 1 — Lineage of K233908, 2001–2024Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in LLZ? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

Top candidate predicates for a new LLZ device

  1. #1 K230955 syngo Application Softwarescore 21.5 · 11 generations · no Class I recall
  2. #2 Held for the reportin the report
  3. #3 Held for the reportin the report
Get a 510(k) Report

What was it cleared against? (1)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K201103Xeleris V Processing and Review Systems
Summary page 4
…e: 510(k) Number Predicate Device Name / Manufacturer Primary Predicate Xeleris V Processing and Review Systems K201103  (DaTQUANT Application) / GE Medic…
GE Healthcare2020—

Also cleared against K201103: 2 other devices →

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 23 years and passes through 7 companies; a new generation was cleared every 1.5 years on median.
  • 7 of the 24 ancestors have a recall of any class.
  • 2 other devices also cite its predicate K201103.

How does its category compare?

All LLZ devices

LLZ System, Image Processing, Radiological: FDA decisions, review times, recalls and adverse event reports over 20 years. 2024, this device’s year, is highlighted.

FDA decisions per year · LLZ

58in 2025

2007: 762008: 942009: 702010: 512011: 1062012: 822013: 952014: 782015: 642016: 822017: 782018: 1042019: 742020: 812021: 832022: 652023: 872024: 622025: 582026 (partial year): 45
2007high 106 (2011) · low 51 (2010)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · LLZ

173in 2025

2007: 36 days median2008: 52 days median2009: 62 days median2010: 98 days median2011: 79 days median2012: 87 days median2013: 84 days median2014: 89 days median2015: 90 days median2016: 90 days median2017: 107 days median2018: 105 days median2019: 107 days median2020: 115 days median2021: 116 days median2022: 137 days median2023: 157 days median2024: 131 days median2025: 173 days median2026 (partial year): 110 days median
2007high 173 (2025) · low 36 (2007)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · LLZ

11in 2025

2007: 202008: 322009: 212010: 172011: 302012: 122013: 642014: 62015: 162016: 122017: 52018: 72019: 22020: 62021: 32022: 42023: 82024: 62025: 112026 (partial year): 14
2007high 64 (2013) · low 2 (2019)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · LLZ

116in 2025

2007: 1522008: 1542009: 1452010: 1452011: 4542012: 2662013: 1,1302014: 15,6312015: 2112016: 2902017: 1042018: 722019: 882020: 822021: 702022: 282023: 262024: 422025: 116
2007high 15,631 (2014) · low 26 (2023)2025

MAUDE reports naming product code LLZ, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007763620152
2008945232154
2009706221145
2010519817145
20111067930454
2012828712266
20139584641,130
20147889615,631
2015649016211
2016829012290
2017781075104
2018104105772
201974107288
202081115682
202183116370
202265137428
202387157826
202462131642
20255817311116
20264511014—

What is it indicated for?

cNeuro™ cDAT is intended for use by Nuclear Medicine or Radiology practitioners and referring physicians for display, processing, and reporting of Nuclear Medicine Imaging data. cNeuro™ cDAT enables visual evaluation and quantification of ioflupane I 123 (DaTscan™) images. The software enables automated quantification of tracer uptake and comparison with the corresponding tracer uptake in healthy subjects as provided by normal population databases of…

Read the full statement (140 words)

cNeuro™ cDAT is intended for use by Nuclear Medicine or Radiology practitioners and referring physicians for display, processing, and reporting of Nuclear Medicine Imaging data.

cNeuro™ cDAT enables visual evaluation and quantification of ioflupane I 123 (DaTscan™) images. The software enables automated quantification of tracer uptake and comparison with the corresponding tracer uptake in healthy subjects as provided by normal population databases of ioflupane I 123 (DaTscan™) images. cNeuro™ cDAT assists in detection of loss of functional dopaminergic neuron terminals in the striatum, which is correlated with Parkinson disease or Dementia with Lewy Bodies (DLB).

cNeuro™ cDAT has not been demonstrated to improve ioflupane I 123 reader performance for distinguishing positive from negative patients. This device should not be used to deviate from ioflupane I 123 dosing and administration instructions. Refer also to ioflupane I 123 prescribing information for instructions.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K233908: cNeuro cDAT.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 4, 2026. https://510kreport.com/device/K233908

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026